Nadeem Kassam

Dr. Nadeem Kassam


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2025 in Life
Verified
Journal Article
Open access
PDF file
MSMunish Sharma
Munish Sharma
VPVivek Paudyal
Vivek Paudyal
SSSaifullah Khalid Syed
Saifullah Khalid Syed
RTRubi Thapa
Rubi Thapa
NKNadeem Kassam
Nadeem Kassam
Salim SuraniSalim Surani
Salim Surani
Primary pulmonary hypertension (PPH), now known as pulmonary arterial hypertension (PAH), has induced significant treatment breakthroughs in the past decade. Treatment has focused on improving patient survival and quality of life, and delaying disease progression. Current therapies are categorized based on targeting different pathways known to contribute to PAH, including endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5 inhibitors), prostacyclin analogs, soluble guanylate cyclase stimulators, and activin signaling inhibitors such as Sotatercept. The latest addition to treatment options is soluble guanylate cyclase stimulators, such as Riociguat, which directly stimulates the nitric oxide pathway, facilitating vasodilation. Looking to the future, advancements in PAH treatment focus on precision medicine involving the sub-stratification of patients through a deep characterization of altered Transforming Growth Factor-β(TGF-β) signaling and molecular therapies. Gene therapy, targeting specific genetic mutations linked to PAH, and cell-based therapies, such as mesenchymal stem cells, are under investigation. Besides prevailing therapies, emerging PH treatments target growth factors and inflammation-modulating pathways, with ongoing trials assessing their long-term benefits and safety. Hence, this review explores current therapies that delay progression and improve survival, as well as future treatments with curative potential.

3 April 2024 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
NKNadeem Kassam
Nadeem Kassam
MNMzee Ngunga
Mzee Ngunga
MVMohamed Varwani
Mohamed Varwani
MMMiriam Msunza
Miriam Msunza
MJMohamed Jeilan
Mohamed Jeilan
Introduction: Acute coronary syndrome (ACS) accounts for coronary artery disease (CAD) –related morbidity and mortality. There has been growing concern about the rising incidence of ACS among young individuals globally both in developed and developing countries, including Sub-Saharan Africa. This group’s phenotypic characteristics; risk factors and clinical outcomes are not well described. contextual and regional studies are necessary to understand the magnitude of ACS among young Individuals and help highlight challenges and opportunities for improved ACS outcomes in the region. The study aimed to describe the demographic and clinical characteristics of young individuals hospitalized with ACS and report on in-hospital outcomes. Methodology: This single-center retrospective study was conducted at the Aga Khan University Hospital, Nairobi. Medical records of all young individuals hospitalized with ACS from 30th June 2020 to 1st May 2023 were reviewed. We defined young individuals as 50 years or below. Categorical variables were reported as frequencies and proportions, and compared with Pearson chi- square or Fisher’s exact tests. Continuous variables were reported as means or medians and compared with independent t-tests or Mann-Whitney U tests. P- value < 0.05 was considered statistically significant. Results: Among 506 patients hospitalized with ACS, (n = 138,27.2%) were aged 50 years and below. The study population was male (n = 107, 79.9%) and African(n = 82,61.2%) predominant with a median age of 46.5 years (IQR 41.0–50.0). Hypertension (n = 101,75.4%) was noted in most study participants. More than half of the cohort were smokers (n = 69,51.5%) having a family history of premature ASCVD(n = 70,52.2%) and were on lipid-lowering therapy(n = 68,50.7%) prior to presentation. ST-segment–elevation myocardial infarction (STEMI) was the most common clinical manifestation of ACS (n = 77, 57.5%). Of the significant coronary artery disease (n = 75,56.0%), the majority of the individuals had single vessel disease (n = 60, 80%) with a predilection of left anterior deciding artery(n = 47,62.6%). The Main cause of ACS was atherosclerosis (n = 41,54.6%). The mean left ventricular ejection fraction was 46.0 (± 12.4). The in-hospital mortality was (n = 2, 1.5%). Conclusion: This study highlights that young individuals contribute to a relatively large proportion of patients presenting with ACS at our center. The most common presentation was STEMI. The principal cause was atherosclerosis. The findings of this study highlight the importance of developing systems of care that enable the early detection of CAD. Traditional cardiovascular risk factors were prevalent and modifiable, thus targets of intervention.

1 January 2024 in Pan African Medical Journal
Verified
Journal Article
Open access
NKNadeem Kassam
Nadeem Kassam
MVMohamed Varwani
Mohamed Varwani
MNMzee Ngunga
Mzee Ngunga
MJMohamed Jeilan
Mohamed Jeilan
MMMangaro Mabusi
Mangaro Mabusi
NJNasiruddin Jamal
Nasiruddin Jamal
INTRODUCTION: Ischemic Heart Disease (IHD) is an emerging epidemic in sub-Saharan Africa (SSA). Despite the true burden to be underreported in the African continent, it still remains the leading cause of death among adults aged above 60 years. ST-Segment Elevation Myocardial Infarction (STEMI) is a clinically time-sensitive fatal sequela of IHD with timely reperfusion by primary Percutaneous Coronary Intervention (PCI) being the gold standard of care. There has been steady progress in coronary care services in Tanzania, alongside a rise in IHD-related risk factors. However, data on this is limited. This study aimed to examine trends in STEMI over the past decade and identify factors associated to in-hospital mortality. METHODS: this single-center retrospective study was conducted at the Aga Khan Hospital Dar-es-Salaam (AKHD), Tanzania. The AKHD is one of the pioneers in establishing the first cardiac catheterization laboratory in the nation. The current study involved extracting relevant data of all patients who presented with STEMI from August 2014 to December 2023. Descriptive statistics were used to define the population. Patient´s outcomes were based on hospital survival. Binary logistic regression was run (at 95% CI and p-value

14 November 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
MVMohamed Hasham Varwani
Mohamed Hasham Varwani
NKNadeem Kassam
Nadeem Kassam
JSJasmit Shah
Jasmit Shah
ABAnders Barasa
Anders Barasa
MNMzee Ngunga
Mzee Ngunga
Heart failure (HF) poses a significant and growing public health challenge in Kenya, largely driven by the increasing prevalence of hypertension, diabetes mellitus, and obesity. The condition disproportionately affects younger adults and is primarily linked to non-ischemic causes. Despite the existence of evidence-based treatment options, major barriers remain—particularly in timely diagnosis, access to care, and long-term management—leading to high rates of hospital readmission and mortality. Additionally, the absence of robust national data limits the development of effective policies and optimized HF care strategies. This study aimed to describe the clinical and demographic characteristics, underlying etiologies, management practices, and short-term outcomes—including in-hospital and six-month mortality—of HF patients in Kenya, utilizing data from the National Research Fund (NRF) Registry on Cardiovascular Diseases. This was a prospective observational study, conducted at three tertiary hospitals in Kenya—Kenyatta National Hospital, Moi Teaching and Referral Hospital, and Aga Khan University Hospital—representing public and private sectors from December 2021 to December 2022. Adults (≥ 18 years) with clinically and objectively confirmed heart failure were enrolled from both inpatient and outpatient settings. Data were managed via REDCap and analyzed using Stata 17.0. Descriptive statistics were used to describe the population. Logistic regression was used to assess survival and predictors of mortality. Statistical significance was set a P value < 0.05. A total of 795 HF patients were enrolled across three tertiary hospitals in Kenya. The mean age was 52.3 years (SD 18.4), 51.7% were female. The majority were of African descent (n = 763, [97.2%]) who presented with new-onset HF (n = 704, [88.6%]). Hypertension was the most common comorbidity (39%). On ECG, 6.3% had left bundle branch block (LBBB). Echocardiographic findings showed that majority (n = 598, [76%]) had a LVEF of < 40%. Most patients (n = 534, [83.3%]) were symptomatic, classified as NYHA class II or higher. In-hospital mortality was 6.6%, and the median length of stay was 8 days. Independent predictors of in-hospital mortality included age > 50 years [OR 2.65 (1.25–5.61)] and NYHA class III/IV symptoms [OR 7.74 (1.02–58.5)]. HF patients in Kenya are predominantly middle-aged and commonly present with new-onset symptoms and reduced LVEF. In-hospital mortality was 6.6% and was independently associated with age over 50 years and advanced symptoms (NYHA class III/IV). These findings highlight the need for earlier detection and more aggressive initial management in this population.

1 December 2023 in Patient Related Outcome Measures
Verified
Journal Article
Open access
PDF file
NKNadeem Kassam
Nadeem Kassam
PAPhilip B Adebayo
Philip B Adebayo
IMIris Martin Matei
Iris Martin Matei
EAEric Aghan
Eric Aghan
SSSamina Somji
Samina Somji
SSSalim Surani
Salim Surani
Introduction: Despite the implementation of complex interventions, ICU mortality remains high and more so in developing countries. The demand for critical care in Sub-Saharan Africa is more than ever before as the region experiences a double burden of rising rates of non-communicable diseases (NCD) in the background battle of combating infectious diseases. Limited studies in Tanzania have reported varying factors associated with markedly high rates of ICU mortality. Investigating the burden of ICU care remains crucial in providing insights into the effectiveness and challenges of critical care delivery. Material and Methods: A single-center retrospective study that reviewed records of all medically admitted patients admitted to the ICU of the Aga Khan Hospital, Dar-es-Salaam, from 1st October 2018 to 30th April 2023. To define the population in the study, we used descriptive statistics. Patients’ outcomes were categorized based on ICU survival. Binary logistic regression was run (at 95% CI and p-value < 0.05) to identify the determinants for ICU mortality. Results: Medical records of 717 patients were reviewed. The cohort was male (n=472,65.8%) and African predominant (n=471,65.7%) with a median age of 58 years (IQR 45.0– 71.0). 17.9% of patients did not survive. The highest mortality was noted amongst patients with septic shock (29.3%). The lowest survival was noted amongst patients requiring three organ support (n=12,2.1%). Advanced age (OR 1.02,CI 1.00– 1.04), having more than three underlying comorbidities (OR 2.50,CI 1.96– 6.60), use of inotropic support (OR 3.58,CI 1.89– 6.80) and mechanical ventilation (OR 9.11,CI 4.72– 18.11) showed association with increased risk for mortality in ICU. Conclusion: The study indicated a much lower ICU mortality rate compared to similar studies conducted in other parts of Sub-Saharan Africa. Advanced age, underlying multiple comorbidities and organ support were associated with ICU mortality. Large multi-center studies are needed to highlight the true burden of critical care illness in Tanzania.

15 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MSMunish Sharma
Munish Sharma
VPVivek Paudyal
Vivek Paudyal
SSSaifullah Khalid Syed
Saifullah Khalid Syed
RTRubi Thapa
Rubi Thapa
NKNadeem Kassam
Nadeem Kassam
Salim SuraniSalim Surani
Salim Surani
Primary pulmonary hypertension (PPH), now known as pulmonary arterial hypertension (PAH), has envisioned significant treatment breakthroughs in the past decade. Treatment has focused on improving patient survival and quality of life and delaying disease progression. Current therapies are categorized based on targeting different pathways known to contribute to PAH, including endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5 inhibitors), prostacyclin analogs, soluble guanylate cyclase stimulators, activin signaling inhibitors as Sotatercept. The latest addition to treatment options is soluble guanylate cyclase stimulators, such as Riociguat, which directly stimulates the nitric oxide pathway, facilitating vasodilation. Looking to the future, advancements in PAH treatment focus on precision medicine involving the sub-stratification of patients through a deep characterization of altered Transforming Growth Factor- β(TGF-β) signaling and molecular therapies. Gene therapy, targeting specific genetic mutations linked to PAH, and cell-based therapies, such as mesenchymal stem cells, are under investigation. Novel pharmacologic targets are also developing, including growth factors and inflammation-modulating pathways. Ongoing clinical trials aim to refine these emerging treatments and better understand their long-term benefits and safety profiles. This review will discuss the current therapies that help delay the progression and improve survival and future PAH treatments that hold potential for curative approaches targeting underlying disease mechanisms.